Plasma β-amyloid in Alzheimer’s disease and vascular disease

[1]  K. Blennow,et al.  CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease , 2016, Annals of clinical and translational neurology.

[2]  K. Blennow,et al.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.

[3]  Harald Hampel,et al.  Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. , 2015, Brain : a journal of neurology.

[4]  K. Blennow,et al.  Amyloid biomarkers in Alzheimer's disease. , 2015, Trends in pharmacological sciences.

[5]  Christoph Laske,et al.  Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. , 2015, Journal of the American College of Cardiology.

[6]  A. Fagan,et al.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease , 2015, Alzheimer's & Dementia.

[7]  D. Michaelson.  APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[8]  D. Rujescu,et al.  Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. , 2014, JAMA psychiatry.

[9]  K. Blennow,et al.  Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. , 2014, JAMA neurology.

[10]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[11]  K. Blennow,et al.  Cerebrospinal fluid analysis in Alzheimer’s disease: technical issues and future developments , 2014, Journal of Neurology.

[12]  H. Kiiveri,et al.  A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study , 2014, Molecular Psychiatry.

[13]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[14]  Sid O'Bryant,et al.  Developing novel blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[15]  Blaine R. Roberts,et al.  Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease , 2014, Alzheimer's & Dementia.

[16]  Karmen K. Yoder,et al.  Association of plasma and cortical amyloid beta is modulated by APOE ε4 status , 2014, Alzheimer's & Dementia.

[17]  Jyrki Lötjönen,et al.  Implementation and Validation of an Adaptive Template Registration Method for 18F-Flutemetamol Imaging Data , 2013, The Journal of Nuclear Medicine.

[18]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[19]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[20]  À. Rovira,et al.  Plasma β-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke , 2012, Neurodegenerative Diseases.

[21]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[22]  Henrik Zetterberg,et al.  Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans , 2011, PloS one.

[23]  C. Jack,et al.  Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI , 2011, Acta Neuropathologica.

[24]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[25]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[26]  Jean-François Dartigues,et al.  Association of Plasma Aß Peptides with Blood Pressure in the Elderly , 2011, PloS one.

[27]  F. Jessen,et al.  Amyloid β peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing , 2010, Experimental Neurology.

[28]  David M. Rissin,et al.  Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.

[29]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[30]  Anders Wallin,et al.  Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.

[31]  D. Werring,et al.  The Microbleed Anatomical Rating Scale (MARS) , 2009, Neurology.

[32]  R. Vandenberghe,et al.  Whole-Body Biodistribution and Radiation Dosimetry of 18F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging , 2009, Journal of Nuclear Medicine.

[33]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease , 2009, Acta Neuropathologica.

[34]  C. Adler,et al.  Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease , 2009, Alzheimer's & Dementia.

[35]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[36]  R. Petersen,et al.  Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease , 2007 .

[37]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[38]  C. Mariani,et al.  Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[39]  Eric E. Smith,et al.  Plasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy , 2006, Neurology.

[40]  C. Broeckhoven,et al.  Hereditary cerebral hemorrhage with amyloidosis dutch type (AβPP 693): decreased plasma amyloid-β 42 concentration , 2003, Neurobiology of Disease.

[41]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[42]  F. Crawford,et al.  Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. , 2003, Neurological research.

[43]  P. Scheltens,et al.  A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT , 2001, Stroke.

[44]  S. Younkin,et al.  Plasma β‐Amyloid Peptide, Transforming Growth Factor‐β1, and Risk for Cerebral Amyloid Angiopathy , 2000 .

[45]  B. Pappas,et al.  Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion , 2000, Neurobiology of Aging.

[46]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[47]  D. Tousoulis,et al.  The Role of Inflammation , 2018 .

[48]  H. Vanderstichele,et al.  Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. , 2012, Journal of Alzheimer's disease : JAD.

[49]  K. Blennow,et al.  Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. , 2012, Journal of Alzheimer's disease : JAD.

[50]  A. Fagan,et al.  Performance characteristics of plasma amyloid-beta 40 and 42 assays. , 2009, Journal of Alzheimer's disease : JAD.

[51]  R. Petersen,et al.  Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. , 2007, Archives of neurology.

[52]  J. Growdon,et al.  Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. , 2006, Neurology.

[53]  A. Hofman,et al.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.

[54]  A. Hofman,et al.  a prospective case-cohort study , 2006 .

[55]  C. van Broeckhoven,et al.  Hereditary cerebral hemorrhage with amyloidosis Dutch type (AbetaPP 693): decreased plasma amyloid-beta 42 concentration. , 2003, Neurobiology of disease.

[56]  L S Honig,et al.  Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. , 2003, Neurology.

[57]  S. Younkin,et al.  Plasma beta-amyloid peptide, transforming growth factor-beta 1, and risk for cerebral amyloid angiopathy. , 2000, Annals of the New York Academy of Sciences.